Welcome to our dedicated page for BioNTech SE American Depositary Share news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BioNTech SE American Depositary Share stock.
BioNTech SE (American Depositary Share - BNTX) is a leading biotechnology company based in Germany, renowned for its pioneering work in the field of immunotherapy and vaccines. BioNTech's core business revolves around developing innovative cancer treatments and vaccines for infectious diseases, including the widely recognized COVID-19 vaccine, Comirnaty, which it co-developed with Pfizer.
BioNTech's oncology pipeline encompasses several advanced drug classes, including mRNA-based drugs that encode antigens, neoantigens, cytokines, and antibodies. The company is also advancing cell therapies, bispecific antibodies, and antibody-drug conjugates, positioning itself at the forefront of cancer treatment innovation.
Partnerships play a crucial role in BioNTech's strategy. The company collaborates with major pharmaceutical giants such as Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, leveraging shared expertise to accelerate the development and commercialization of its therapies. Recent strategic collaborations include an agreement with MediLink Therapeutics to utilize their TMALIN® antibody-drug conjugate platform, enhancing BioNTech's capabilities in targeting novel cancer therapeutics.
BioNTech's financial health is robust, bolstered by the commercial success of Comirnaty and ongoing strategic partnerships. The company's commitment to innovation and excellence is reflected in its continuous efforts to develop new therapeutics and vaccines, ensuring significant contributions to global healthcare.
For more detailed information, visit the company's official website at www.BioNTech.com.
BioNTech has announced an exclusive collaboration with DualityBio, acquiring rights to two investigational antibody-drug conjugates (ADCs), DB-1303 and DB-1311. This partnership is expected to enhance BioNTech's immunotherapy offerings in cancer treatment. DualityBio will receive $170 million upfront, with potential payments exceeding $1.5 billion based on development milestones, plus royalties on future sales. DB-1303, currently in Phase 2 trials, targets HER2-expressing cancers, and both ADCs aim to broaden precision medicine options in oncology.
BioNTech SE (Nasdaq: BNTX) announced a new share repurchase program to acquire up to $0.5 billion of its American Depositary Shares (ADS) through 2023. This program follows a previous buyback that concluded in March 2023, where $1.3 billion was repurchased. The repurchased ADSs will be used to meet settlement obligations under share-based payment arrangements. The timing of these purchases will be contingent upon market conditions. The program complies with the Securities Exchange Act safe harbor provisions.
BioNTech SE (BNTX) reported strong financial results for 2022, with total revenues of €17.3 billion and a net profit of €9.4 billion, translating to fully diluted earnings per share of €37.77. Approximately 2 billion doses of COMIRNATY® were invoiced in 2022, bolstered by the release of Omicron-adapted vaccines. The company initiated multiple clinical trials, expanding its oncology pipeline to 20 programs and 24 ongoing trials. For 2023, BioNTech estimates COVID-19 vaccine revenues around €5 billion, despite anticipated seasonal demand fluctuations. A share repurchase program of up to $0.5 billion is expected to be authorized in 2023.
BioNTech has entered an exclusive worldwide license with OncoC4 to develop and commercialize the anti-CTLA-4 antibody candidate ONC-392. This collaboration involves co-developing ONC-392 either as monotherapy or in combination with anti-PD1 therapies in various cancer types, with a randomized Phase 3 trial set for 2023. OncoC4 will receive a $200 million upfront payment and potential milestone payments, along with tiered royalties. ONC-392, currently in ongoing trials, has shown promising clinical results and received Fast Track designation from the FDA for treating immunotherapy-resistant non-small cell lung cancer (NSCLC).
BioNTech SE (Nasdaq: BNTX) will announce its financial results for the full year and fourth quarter of 2022 on March 27, 2023. This announcement will be followed by a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss the results and provide a corporate update. Interested participants can register for the conference call via a provided link and access the presentation materials on the Company's website. BioNTech is focused on developing novel therapies for cancer and infectious diseases, leveraging its expertise in mRNA technology.
BioNTech SE (Nasdaq: BNTX) and the Weizmann Institute of Science have entered a Memorandum of Understanding to collaborate on research aimed at understanding diseases such as cancer and neurodegenerative conditions. This partnership will facilitate research at BioNTech’s newly established mRNA Excellence Center in Israel, set to operate by the end of 2023, hosting around 60 researchers across various disciplines. Additionally, BioNTech plans to establish an mRNA manufacturing facility in Israel to advance cancer therapies and enhance health threat responses.
BioNTech SE (Nasdaq: BNTX) has completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany, with an investment of approximately €40 million. This facility aims to enhance the company's autonomy in producing essential components for its mRNA and cell-based therapies, notably for oncology and COVID-19 vaccines. The clinical-scale plant is already operational, while the commercial-scale plant is expected to begin by the end of 2023, pending regulatory approval. The site supports BioNTech's plan to manufacture plasmids for hundreds of millions of vaccine doses annually, contributing to local production and pandemic preparedness.
BioNTech has announced its acquisition of InstaDeep for approximately £362 million in cash and shares, aiming to enhance its AI-driven capabilities in drug discovery and development. This acquisition will add around 240 skilled professionals and strengthen BioNTech's research network across key global technology hubs. InstaDeep will operate as a subsidiary, further integrating AI and ML technologies into BioNTech's operations. The deal is expected to close in the first half of 2023, subject to regulatory approval, and involves potential future milestone payments of up to £200 million.
BioNTech signed a Memorandum of Understanding with the UK Government to enhance clinical trials for personalized cancer immunotherapies. The collaboration aims to provide treatments for up to 10,000 patients by 2030. This multi-year effort will focus on cancer immunotherapies, infectious disease vaccines, and expanding BioNTech's presence in the UK. A new R&D hub in Cambridge will employ over 70 scientists. The first patient is expected to enroll in clinical trials by H2 2023.
BioNTech (Nasdaq: BNTX) announced that CEO Prof. Ugur Sahin will present an overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 9:45 am PST / 12:45 pm ET. A live webcast will be available on the Company's website and will be archived for 30 days. BioNTech is a leader in immunotherapy, focused on innovative therapies for cancer and infectious diseases, leveraging cutting-edge mRNA technology. The Company collaborates with various global pharmaceutical partners to advance its diverse oncology and vaccine pipeline.
FAQ
What is the current stock price of BioNTech SE American Depositary Share (BNTX)?
What is the market cap of BioNTech SE American Depositary Share (BNTX)?
What does BioNTech SE do?
Where is BioNTech SE based?
What is BioNTech's most well-known product?
Who are BioNTech's major partners?
What types of cancer therapies is BioNTech developing?
What is the TMALIN® platform?
How can investors find more information about BioNTech?
What recent collaboration has BioNTech announced?
What is BioNTech's role in the fight against COVID-19?